-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Transcode Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2025.
- Transcode Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$4.22M, a 17.5% increase year-over-year.
- Transcode Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$14.7M, a 17.7% increase year-over-year.
- Transcode Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$15.7M, a 19.4% increase from 2023.
- Transcode Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$19.4M, a 4.21% decline from 2022.
- Transcode Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$18.6M, a 203% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)